"There are basically no published human efficacy trials for BPC-157." Phillips says all he can find is one small safety study from a decade ago, and a trial that only started enrolling participants this past February
While TB-500 is designed around the active region of the larger peptide, the two are not chemically identical, and findings surrounding one cannot automatically be applied to the other
Even less is known about how these reasons differ between those using GLP-1 RAs as anti-obesity medications (AOMs) versus those using them for antidiabetic management (ADMs), or how these patterns have changed over time as awareness, access, and prescribing practices have evolved
However, individuals should consult healthcare providers before use, particularly if they have underlying conditions or take other medications, Dr
Due to its biological characteristics, the precise senolytic mechanism of piperlongumine remains unclear
Tirzepatide remains on the FDA shortage list